Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

This study has been completed.
Sponsor:
Information provided by:
University Ghent
ClinicalTrials.gov Identifier:
NCT00263159
First received: December 6, 2005
Last updated: December 19, 2007
Last verified: December 2007
  Purpose

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.


Condition Intervention
Asthma
Procedure: Pharmaceutical care for asthma patients

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Pharmaceutical Care for Asthma Control Improvement

Further study details as provided by University Ghent:

Primary Outcome Measures:
  • The difference between study groups in the change of asthma control from baseline and follow-up visits [ Time Frame: after 1, 3 and 6 months ]

Secondary Outcome Measures:
  • Peak flow [ Time Frame: after 3 and 6 months ]
  • Knowledge of asthma and treatment [ Time Frame: after 6 months ]
  • Asthma quality of life questionnaire (AQLQ) [ Time Frame: after 6 months ]
  • Therapy adherence
  • Inhalation techniques [ Time Frame: after 6 months ]
  • Smoking [ Time Frame: after 6 months ]
  • Asthma exacerbations [ Time Frame: after 6 months ]
  • General Practitioner (GP) visits, emergency room visits and hospitalisations
  • Working days lost and school days lost

Enrollment: 221
Study Start Date: January 2006
Study Completion Date: October 2006
Detailed Description:

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients. Patients will be randomly allocated to the control group (= no input from pharmacist) or intervention group (= with pharmaceutical care at baseline and follow-up visits over 6 months).

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with persistent asthma
  • Asthma treatment for at least 12 months
  • Regular visitors of the participating community pharmacy

Exclusion Criteria:

  • Severe co-morbidity
  • > 10 pack-years smoking history
  • Asthma Control Test score < 15 or =25
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00263159

Locations
Belgium
University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Ghent
Investigators
Principal Investigator: Guy Brusselle, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00263159     History of Changes
Other Study ID Numbers: 2005/320
Study First Received: December 6, 2005
Last Updated: December 19, 2007
Health Authority: Belgium: Institutional Review Board

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 25, 2014